Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their medical use and to medicaments comprising them.

Abstract: A smoothing method for suppressing fluctuating artifacts in the reduction of interference noise includes the following steps: providing short-term spectra for a sequence of signal frames, transforming each short-term spectrum by way of a forward transformation which describes the short-term spectrum using transformation coefficients that represent the short-term spectrum subdivided into its coarse and fine structures; smoothing the transformation coefficients with the respective same coefficient indices by combining at least two successive transformed short-term spectra; and transforming the smoothed transformation coefficients into smoothed short-term spectra by way of a backward transformation.

Abstract: A method for determining unbiased signal amplitude estimates () after cepstral variance modification of a discrete time domain signal (s(t)), wherein the cepstrally-modified spectral amplitudes () of the discrete time domain signal (s(t)) are X-distributed with 2{tilde over (?)} degrees of freedom. A bias reduction factor (r) is determined using the equation r 2 = ? ? ~ ? ? ? ? ( ? ~ ) - ? ? ( ? ) , where 2? are the degrees of freedom of the X-distributed spectral amplitudes of the discrete time domain signal (s(t)) and ? ? ( x ) = - 0.5772 - ? n = 0 ? ? ( 1 x + n - 1 1 + n ) ; then the unbiased signal amplitude estimates () are determined by multiplying the cepstrally-modified spectral amplitudes () with the bias reduction factor (r) according to the equation =.

Abstract: The invention relates to novel cyclic compounds of the formula (I), in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.

Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their use as medicaments and to medicaments comprising them.

Abstract: A method for modification of a cepstro-temporally smoothed gain function of a gain function resulting in a bias compensated spectral gain function is provided. The cepstro-temporal smoothing increases the quality of an enhanced output signal, as it affects only spectral outliers caused by estimation errors, while the speech characteristics are well preserved. However, due to the cepstral transform, the temporal smoothing is done in the logarithmic domain rather than the linear domain, and hence results in a certain bias. Thus, the method for a general bias compensation for a cepstro-temporal smoothing of spectral filter gain functions that is only dependent on the lower limit of the spectral filter-gain function.

Abstract: The invention specifies a method for noise reduction of an input signal of a hearing device. The cepstrum coefficients of the input signal, of the changed input signal and/or of at least one parameter obtained from the input signal are modified. The modified cepstral coefficients are used for formation of an output signal from the input signal. The output signal has reduced noise in relation to the input signal. With instationary noises in particular, an estimation is improved and an improved auditive quality is achieved for the hearing device.

Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their use as medicaments and to medicaments comprising them.

Abstract: A pressure sensor including: A pressure measuring cell having an end face loadable with the medium; a housing having a media opening and a ring-shaped, axial bearing surface, which surrounds the media opening; a clamping apparatus; and a ring-shaped sealing arrangement. The pressure measuring cell is positioned in the housing and the sealing arrangement is positioned between the bearing surface and the end face, and the sealing arrangement, as well as the pressure measuring cell, are axially clamped between the bearing surface and the clamping apparatus. The sealing arrangement includes, a decoupling ring, as well as a first and a second, ring-shaped sealing element. The first sealing element lies against the end face, the second sealing element lies against the bearing surface, and the decoupling ring is axially clamped between the first and the second sealing elements.

Abstract: This invention is concerned with compounds of the formula wherein A, R1 to R5 are as defined in the specification and G is a pyridine, quinoline or pyrimidine group as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

Abstract: The invention is concerned with novel benzimidazole derivatives of formula (I) wherein R1 to R8 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to Farnesoid-X-receptors (FXR) and can be used to treat diseases which are modulated by FXR agonists such as diabetes and dyslipidemia.

Abstract: This invention is concerned with compounds of the formula wherein X, A, B, R1, R2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

Abstract: A pressure sensor including: A pressure measuring cell having an end face loadable with the medium; a housing having a media opening and a ring-shaped, axial bearing surface, which surrounds the media opening; a clamping apparatus; and a ring-shaped sealing arrangement. The pressure measuring cell is positioned in the housing and the sealing arrangement is positioned between the bearing surface and the end face, and the sealing arrangement, as well as the pressure measuring cell, are axially clamped between the bearing surface and the clamping apparatus. The sealing arrangement includes, a decoupling ring, as well as a first and a second, ring-shaped sealing element. The first sealing element lies against the end face, the second sealing element lies against the bearing surface, and the decoupling ring is axially clamped between the first and the second sealing elements.

Abstract: This invention is concerned with compounds of the formula wherein R1 to R5, R5? and A are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

Abstract: The pressure sensor of the invention, with an internal hydraulic system for pressure transfer, has a seal enabling an exact fill volume for the hydraulic system.

Abstract: The pressure sensor of the invention, with an internal hydraulic system for pressure transfer, has a seal enabling an exact fill volume for the hydraulic system.

Abstract: This invention is concerned with compounds of the formula wherein A, B1, B2, R1, R2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

Abstract: The present invention relates to compositions and methods for treating obesity. More particularly, the invention relates to a composition comprising a lipase inhibitor such as orlistat, and glucomannan such as konjac as well as methods for utilizing such compositions and kits for carrying out this method.

Abstract: The invention relates to optical devices comprising a substrate and at least one semiconductive polymer supported by said substrate, wherein said semiconductive polymer is a copolymer in which one of the repeat units is a group of formula (I) or a homopolymer in which the repeat unit is a group of formula (I): wherein: A and B are the same or different and each comprises wholly or partially an aryl moiety or a heteroaryl moiety, said moiety in A being fused to the bond a-b and said moiety in B being fused to the bond c-d, and X is a linking unit, X being such that there is a torsion angle of at least 5° between the bond a-b and the bond c-d about the bond b-d. The invention also relates to semiconductive polymers, monomers for preparing same, and methods for preparing random statistical conjugated polymers.

Abstract: Pharmaceutical compositions that contain a lipase inhibitor having a melting point ?37° C., a sucrose fatty acid ester wherein the sucrose fatty acid ester is a mono-, di-, tri- or tetra-ester, and optionally one or more pharmaceutically acceptable excipients, are useful for treatment of obesity.